Abstract:HomeHypertensionVol. 50, No. 1Central Blood Pressure Measurements and Antihypertensive Therapy Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplementary MaterialsFree AccessResearch ArticlePDF/EPUBCentral Blood Pressure Measurements and Antihypertensive TherapyA Consensus Document Enrico Agabiti-Rosei, Giuseppe Mancia, Michael F. O’Rourke, Mary J. Roman, Michel E. Safar, Harold Smulyan, Ji-Guang Wang, Ian B. Wilkinson, Bryan Williams and Charalambos Vlachopoulos Enrico Agabiti-RoseiEnrico Agabiti-Rosei From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Giuseppe ManciaGiuseppe Mancia From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Michael F. O’RourkeMichael F. O’Rourke From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Mary J. RomanMary J. Roman From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Michel E. SafarMichel E. Safar From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Harold SmulyanHarold Smulyan From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Ji-Guang WangJi-Guang Wang From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Ian B. WilkinsonIan B. Wilkinson From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author , Bryan WilliamsBryan Williams From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author and Charalambos VlachopoulosCharalambos Vlachopoulos From the Clinica Medica and Department of Medicine (E.A-R.), University Hospital, Brescia, Italy; Clinica Medica and Department of Medicine (G.M.), University of Milano-Bicocca, St Gerardo Hospital, Monza, Milan, Italy; St Vincent’s Clinic/University of New South Wales (M.F.O.), Darlinghurst, Australia; Weill Medical College (M.J.R.), Cornell University, Ithaca, NY; Centre de Diagnostic (M.E.S.), Hopital Hotel-Dieu, Paris, France; Department of Medicine (H.S.), Upstate Medical University, Syracuse, NY; Centre for Epidemiological Studies and Clinical Trials (J.G.W.), Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; University of Cambridge Addenbrooke’s Hospital (I.B.W.), Cambridge, United Kingdom; the Department of Cardiovascular Sciences (B.W.), School of Medicine, University of Leicester, Leicester, United Kingdom; and the First Department of Cardiology (C.V.), Athens Medical School, Hippokration Hospital, Athens, Greece. Search for more papers by this author Originally published11 Jun 2007https://doi.org/10.1161/HYPERTENSIONAHA.107.090068Hypertension. 2007;50:154–160Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: June 11, 2007: Previous Version 1 The 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension1 included 2 important novel recommendations: assessment of the total cardiovascular risk should be taken into account in the management of the hypertensive patient, and quantification of risk should include subclinical target organ damage.These guidelines acknowledged that central (aortic) blood pressure (BP), which is the pressure exerted on the heart and brain, may be different from the pressure that is measured at the arm. They also recognized that central pressure may be predictive of outcome in specific populations2 and differently affected by antihypertensive drugs. However, although these guidelines accepted that central augmentation index and pulse wave velocity may be important as measures of subclinical organ damage, they also stressed the need for prospective trials to establish their predictive values given that such studies were lacking at that time (2003).After publication of these guidelines, additional data have strengthened the pathophysiological importance of central BP. Clinical studies have indicated that central BP may have predictive value independent of the corresponding peripheral (brachial) BP. More importantly, recent large-scale trials have shown that central hemodynamics may provide a worthwhile treatment target. In addition, central hemodynamics can now be reliably assessed noninvasively with a number of devices. Accordingly, because arterial stiffening and central hemodynamics are markers and manifestations of organ damage, the pertinent key question is whether the balance of evidence on their importance and issues related to clinical practice allows for implementation in patient management.Pathophysiological Significance of Central PressuresCentral (aortic and carotid) pressures are pathophysiologically more relevant than peripheral pressures for the pathogenesis of cardiovascular disease.3,4 It is aortic systolic pressure that the left ventricle encounters during systole (afterload), and the aortic pressure during diastole is a determinant of coronary perfusion. Furthermore, the distending pressure in the large elastic-type arteries (aorta and carotid) is a key determinant of the degenerative changes that characterize accelerated aging and hypertension. In contrast, the muscular peripheral arteries, such as the brachial and the radial ones, are less influenced by these changes.5The pressure wave generated by the left ventricle travels down the arterial tree and then is reflected at multiple peripheral sites, mainly at resistance arteries (small muscular arteries and arterioles). Consequently, the pressure waveform recorded at any site of the arterial tree is the sum of the forward traveling waveform generated by left ventricular ejection and the backward traveling wave, the “echo” of the incident wave reflected at peripheral sites. When the large conduit arteries are healthy and compliant, the reflected wave merges with the incident in the proximal aorta during diastole, thereby augmenting the diastolic BP and aiding coronary perfusion. In contrast, when the arteries are stiff, pulse wave velocity increases, accelerating the incident and reflected waves; thus, the reflected wave merges with the incident wave in systole and augments aortic systolic rather than diastolic pressure. As a result, left ventricular afterload increases, and normal ventricular relaxation and coronary filling are compromised. Apart from changes in the timing of the waveforms merging, changes in the magnitude of the reflected wave and central pressures may result from changes in the proportion of the incident wave that is reflected, which in turn depends on the balance between vasoconstriction and vasodilatation in the peripheral circulation.Another important consideration regarding the relationship between brachial and central aortic pressure is “pressure wave amplification.” Typically, the diastolic and mean pressures change little across the arterial tree. However, systolic BP is amplified when moving from the aorta to the periphery (Figure 1).3Download figureDownload PowerPointFigure 1. Change in contours in pressure wave (top) and flow wave (bottom) between the ascending aorta and the saphenous artery (reprinted from Reference 3).Consequently, the pulsatile components of central and peripheral pressures (systolic BP and pulse pressure [PP]) may vary significantly. In general, brachial systolic and PP tend to overestimate central systolic and PP, especially in younger subjects who have more pronounced amplification. Substantial differences between central and brachial BP are also often also seen in older people, especially with tachycardia, exercise, use of vasoactive agents, or in those with systolic heart failure.Techniques to Assess Central HemodynamicsAlthough central pressures are ideally measured directly by using invasive devices, several methods have been devised currently to derive central pressures from analyses of applanated carotid and radial pulses or carotid distension waves.6 Among several commercial and noncommercial devices,3,6–11 the most widely used in clinical studies is the SphygmoCor device (AtCor Medical), which uses radial or carotid pulses and a validated generalized transfer function to estimate central pressures from the peripheral signal (Figure 2). When the applanated radial waveform is calibrated using direct intra-arterial pressures, the SphygmoCor calculations of aortic pressures are accurate,8,12 whereas the accuracy of this, as well as of other peripheral artery methods, decreases when the radial pulses are calibrated using inaccurate cuff pressures.13 This is also the case for carotid artery techniques. Alternatively, because mean BP remains virtually constant from central to peripheral arteries, the mean BP value computed from the area of the applanated carotid artery waveform can be calibrated using the mean BP obtained at the brachial artery level. Values of carotid pressures can then be derived.6,11 It should be emphasized that even when central pressures cannot be accurately calculated, these methods can display several features of the aortic (or carotid) pulse that are not dependent on the absolute values of BP, such as amplification of the pulse wave between central and peripheral artery, augmentation index, and arrival time of the reflected wave (the latter 2 are, however, dependent on identification of inflection point). Furthermore, because these features are also influenced by factors including heart rate, height, and age, modern computational capability could allow weighting of these factors in appropriate formulas. Potential problems related to the widespread application of arterial tonometry include appropriate training, supervision, and quality control, as they do for sphygmomanometry. Download figureDownload PowerPointFigure 2. Central pressure waveform. The height of the late systolic peak above the inflection defines the augmented pressure, and the ratio of augmented pressure to PP defines the augmentation index (in percentage; modified from Reference 6).Arterial wave reflections indices and central pressures coupled with measurement of aortic pulse wave velocity, a direct measure of arterial stiffness, constitute a comprehensive and integrated approach of the study of arterial function.6 This is further highlighted by a possible differential ability to predict risk (augmentation index is better in younger persons and pulse wave velocity is better in older persons14) or by situations where, contrary to the usual behavior, pulse wave velocity and wave reflection indices move in opposite directions.15Central Pressures and Central Indices as Markers and Predictors of DiseaseCentral hemodynamic variables have been shown to be independently associated with organ damage, incident cardiovascular disease, and events both in the general population and in various disease states.2,16–40Tables 1 and 2 show such associations according to population studied, variable measured, and site and mode (invasive or noninvasive) of measurement. TABLE 1. Cross-Sectional and Longitudinal Studies Indicating the Independent Value of Central Hemodynamics as Markers of Disease and Predictors of Surrogate Cardiovascular End PointsSourceYear, CountryPopulationDesignParameterEnd PointAIx indicates augmentation index; CAD, coronary artery disease; CV, cardiovascular; FU, follow-up; IMT, intima–media thickness; LV, left ventricular; LVMI, left ventricular mass index.*Central pressure measured directly.†These studies have shown incremental value of central indices over peripheral BP.Saba et al16*†1993, United StatesNormotensivesCross-sectionalCarotid AIxLVMI, carotid thicknessBoutouyrie et al17*†1999, FranceHypertensivesCross-sectionalCarotid PPCarotid thicknessBoutouyrie et al18*†2000, FranceHypertensivesLongitudinal (9-month FU)Carotid PPCarotid IMT reduction with treatmentRoman et al192000, United StatesNormotensives, HypertensivesCross-sectionalCarotid systolic BPRelative LV wall thicknessWaddell et al20*†2001, AustraliaCADCross-sectionalCarotid BPExtent of CADNishijima et al21*2001, JapanSuspected CADCross-sectionalAortic fractional PPIncident CADNurnberger et al222002, GermanyHealthy+CVDCross-sectionalCarotid AIxCV risk scoresPhilippe et al23*2002, FranceCADCross-sectionalAortic PPExtent of CADHayashi et al24*2002, JapanSuspected CADCross-sectionalAortic AIxIncident CADDe Luca et al25†2004, REASON StudyHypertensivesLongitudinal (1-year FU)Carotid PPLVMI reductionWeber et al262004, AustriaSuspected CADCross-sectionalAortic AP, AIxIncident CADJankowski et al27*2004, PolandCADCross-sectionalAortic BPExtent of CADDanchin et al28*2004, FranceSuspected CADCross-sectionalAortic PPIncidence and extent of CADBooth et al292004, United KingdomSystemic vasculitisCross-sectionalAortic AIxDisease activityRoman et al302007, United StatesHigh-riskCross-sectionalAortic PPCarotid IMT and massHashimoto et al31†2007, JapanHypertensivesLongitudinal (1-year FU)Aortic AIxLVMI reduction with treatmentTABLE 2. Longitudinal Studies Indicating the Independent Value of Central Hemodynamics as Predictors of EventsSourceYear, countryPopulationDesignParameterEnd PointESRD indicates end-stage renal disease; PTCA, percutaneous transluminal coronary angioplasty; AIx, augmentation index; CAD, coronary artery disease; CV, cardiovascular; FU, follow-up.*Central pressure measured directly.†These studies have shown incremental value of central indices over peripheral BP.Nakayama et al32*2000, JapanCAD-PTCALongitudinal (3-mo FU)Aortic fractional PPRestenosisLu et al33*2001, ChinaCAD-PTCALongitudinal (6-mo FU)Aortic PPRestenosisLondon et al34†2001, FranceESRDLongitudinal (52-mo FU)Carotid AIxCV mortalitySafar et al2†2002, FranceESRDLongitudinal (52-mo FU)Carotid PP, PP amplificationAll-cause and CV mortalityUeda et al35*2004, JapanCAD-PTCALongitudinal (6-mo FU)Aortic AIxRestenosisChirinos et al36*†2005, United StatesCADLongitudinal (3.2-y FU)Aortic APCV mortality and eventsWeber et al37†2005, AustriaCAD-PTCALongitudinal (2-y FU)Aortic AIxCV mortality and eventsDart et al382006, AustraliaElderly female hypertensivesLongitudinal (4.1-y FU)Carotid AIx, brachial BPCV mortality and eventsWilliams et al39†2006 CAFE StudyHypertensivesLongitudinal (≤4-y FU)Aortic PPCV mortality and events during treatmentRoman et al30,40†2005 and 2007, United StatesHigh-riskLongitudinal (4.8-y FU)Aortic PPCV mortality and eventsCentral Pressures and Central Indices as Markers of Disease and Predictors of Surrogate End PointsIncreased aortic augmentation index is associated with coronary artery disease.26 Central pressures also correlate with cardiovascular risk not only in patients with atherosclerotic disease but also in apparently healthy subjects.22 The late systolic augmentation of the central pressure waveform is associated with an increase in left ventricular mass index independent of age and mean BP,16,31 and carotid systolic BP is an independent determinant of left ventricular wall thickness.19 Moreover, central pressure is also more closely related to other important cardiovascular intermediate end points, such as vascular hypertrophy, extent of carotid atherosclerosis,17,30 and the ascending aorta diameter in patients with Marfan syndrome41 than brachial pressure. Recently, higher carotid pressure augmentation in older individuals has been linked to increased flow pulsations entering the cerebral circulation, which may increase the risk of cerebral microvascular damage.42 In inflammatory disorders such as systemic vasculitis, augmentation index is a marker of disease activity, and it is independently associated with levels of C-reactive protein.29Central Pressures and Central Indices as Predictors of EventsRecent data from the Strong Heart Study confirm that peripheral PP, a simple index of arterial stiffness, is associated with a higher cardiovascular mortality independent of traditional risk factors, left ventricular hypertrophy, and reduced ejection fraction in adults without overt coronary heart disease.43 Furthermore, data from the same study showed in a 5-year follow-up that the noninvasively determined central PP better predicts incident cardiovascular disease than does the corresponding brachial PP, possibly because of a more accurate representation of the vascular load on the left ventricle.30,40 The predictive value of central PP is significant even when subclinical atherosclerosis is taken into account.30,40 Central pressures and wave reflection indices are also strong independent predictors of all-cause and cardiovascular mortality in patients with end-stage renal failure.2,34 Moreover, in patients with coronary artery disease, wave reflections as expressed by central augmented pressure are powerful and independent predictors of recurrent acute coronary events or death.36 Pulsatility of the ascending aortic pressure waveform is a powerful predictor of restenosis after angioplasty.32,33 Moreover, increased arterial wave reflections expressed by augmentation index are independently associated with an increased risk of severe short- and long-term cardiovascular events in patients undergoing percutaneous coronary interventions.37 In contrast to the aforementioned evidence, a recent study conducted in elderly hypertensive women found that carotid augmentation index is not predictive of outcome.38 However, the large Conduit Artery Function Evaluation (CAFE) Study reported that central PP derived from radial artery applanation tonometry independently predicts outcome in treated patients with hypertension.39 Highlighting the interplay of small and large arteries in risk determination, the structure of small arteries (which compose the main peripheral reflecting sites) was a predictor of events in patients with hypertension.44It should be noted, however, that evidence for a specific central pressure component or index does not necessarily apply to the others, and, thus, they should not be used interchangeably. Furthermore, there is clearly a need for additional studies of central pressures and indices in more general populations or in other disease states. Finally, it would be desirable for future studies to address whether central pressures provide incremental and independent prognostic value over other emerging biomarkers.Implications for TherapyBP reduction, per se, is the major determinant of the benefit of antihypertensive treatment. This has been shown by data from placebo-controlled trials, trials that compared more intensive versus less intensive BP-lowering strategies, and trials comparing different active regimens, and it is further supported by large meta-analyses of studies on antihypertensive treatment1,45–47 (Figure 3). Download figureDownload PowerPointFigure 3. Metaregression line relating the within-trial difference in systolic BP to the odds ratios for stroke. Odds ratios were calculated for experimental vs reference treatment. BP differences were obtained by subtracting achieved levels in experimental groups from those in reference groups. At left, pressure is the brachial measured, whereas at right, pressure is the estimated central pressure allowed for the decrease over brachial pressure of 3 mm Hg when the active therapy was a drug that reduces peripheral wave reflection (calcium channel blocker, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker). The curvilinear metaregression line (left) becomes linear (right) when central rather than peripheral pressures are plotted against odds ratios, indicating a direct relation between cardiovascular outcome and pressure changes induced by antihypertensive treatment (from References 3 and 45).However, during the last decade, important multicenter trials gave rise to the hypothesis that new antihypertensive drugs, such as blockers of the renin–angiotensin system, may reduce cardiovascular outcomes beyond (peripheral) BP control. Particularly, in the Heart Outcomes Prevention Evaluation (HOPE), Losartan Intervention For Endpoint reduction in hypertension (LIFE), and the Australian National Blood Pressure 2 (ANBP2) studies, the observed clinical benefit tended to be greater than that expected from the decrease in peripheral BP. These potential effects “beyond BP control” are perhaps accounted for by protective properties of different drugs that affect subclinical organ damage or intermediate end points, such as arterial properties or central BP, for which there is evidence that they are related to cardiovascular morbidity and mortality.1,48 Effects on central pressures may not be evident by pressure measurements in the periphery, because the reflected wave is added to a different part of the central waveform.49 This may explain why drugs with similar reduction in peripheral pressures have a differential impact on cardiovascular outcomes. In this context, a short-term (4-week treatment) study showed that, in contrast to β-blocking drugs, angiotensin-converting enzyme inhibitors and calcium blockers may be more effective in reducing aortic systolic BP than that indicated by brachial pressure measurements.50 Furthermore, more recent studies comparing the acute effects of angiotensin-converting enzyme inhibitors (ramipril) and the short-term (6-week) effects of angiotensin receptor blockers (eprosartan) with atenolol showed that, for a similar fall of brachial pressure, inhibitors of the renin–angiotensin axis may cause a significantly greater fall o

Abstract:HomeJournal of the American Heart AssociationVol. 12, No. 20Highlights From the American Heart Association's EPI|Lifestyle Scientific Sessions 2023 Open AccessMeeting ReportPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessMeeting ReportPDF/EPUBHighlights From the American Heart Association's EPI|Lifestyle Scientific Sessions 2023 Amelia S. Wallace, Oluwabunmi Ogungbe, Elisabeth L. P. Sattler, Emily Aidoo, Tara S. Allen, Lauren Bernard, Yingan Chen, Shutong Du, Taynara Formagini, Bamba Gaye, Ben King, Sohyeon Kwon, Fredrick Larbi Kwapong, Tiange Liu, Nour Makarem, Heidy Mendez‐Rodriguez, Faith E. Metlock, Shirine Moukaled, Amy R. Nichols, Bige Ozkan, Rupal Trivedi, Ruth‐Alma Turkson‐Ocran, Frances M. Wang, Caroline Wang, Yunwen Xu, Christina Y. Yin, Mingyu Zhang, Alvaro Alonso and Marie‐France Hivert Amelia S. WallaceAmelia S. Wallace * Correspondence to: Amelia S. Wallace, PhD, MS, Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research and the Johns Hopkins Bloomberg School of Public Health; 2024 E Monument Street, Suite 2‐600; Baltimore, MD 21287. Email: E-mail Address: [email protected] https://orcid.org/0000-0002-1466-3791 , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Oluwabunmi OgungbeOluwabunmi Ogungbe https://orcid.org/0000-0003-1813-0906 , Johns Hopkins School of Nursing, , Baltimore, , MD, , USA, , Elisabeth L. P. SattlerElisabeth L. P. Sattler https://orcid.org/0000-0002-6379-7892 , Department of Clinical and Administrative Pharmacy, College of Pharmacy, , University of Georgia, , Athens, , GA, , USA, , Department of Nutritional Sciences, College of Family and Consumer Sciences, , University of Georgia, , Athens, , GA, , USA, , Emily AidooEmily Aidoo https://orcid.org/0000-0002-8959-505X , Department of General Medicine, Beth Israel Deaconess Medical Center, , Harvard Medical School, , Boston, , MA, , USA, , Tara S. AllenTara S. Allen , Division of Preventive Medicine, Department of Family Medicine, , University of California, San Diego, , San Diego, , CA, , USA, , Lauren BernardLauren Bernard https://orcid.org/0000-0001-5747-3747 , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Yingan ChenYingan Chen , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Shutong DuShutong Du , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Taynara FormaginiTaynara Formagini https://orcid.org/0000-0001-9318-5734 , Department of Family Medicine and Public Health, , University of California San Diego, , San Diego, , CA, , USA, , Institute for Behavioral & Community Health, , San Diego State University, , San Diego, , CA, , USA, , Bamba GayeBamba Gaye https://orcid.org/0000-0002-5516-4665 , Department of Epidemiology, , INSERM, U970, Paris Cardiovascular Research Center, , Paris, , France, , Paris Cardiovascular Research Centre, , Université de Paris, INSERM, , Paris, , France, , Ben KingBen King , Tilman J Fertitta Family College of Medicine, Department of Health Systems and Population Health Sciences, , University of Houston, , Houston, , TX, , USA, , Humana Integrated Health Systems Sciences Institute, , University of Houston, , Houston, , TX, , USA, , Sohyeon KwonSohyeon Kwon https://orcid.org/0000-0003-2307-4160 , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Fredrick Larbi KwapongFredrick Larbi Kwapong https://orcid.org/0000-0002-5585-632X , Department of General Medicine, Beth Israel Deaconess Medical Center, , Harvard Medical School, , Boston, , MA, , USA, , Tiange LiuTiange Liu https://orcid.org/0000-0003-2486-8691 , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Nour MakaremNour Makarem https://orcid.org/0000-0001-5230-8689 , Department of Epidemiology, Mailman School of Public Health, , Columbia University Irving Medical Center, , New York, , NY, , USA, , Heidy Mendez‐RodriguezHeidy Mendez‐Rodriguez https://orcid.org/0000-0002-7803-6770 , San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, , San Diego, , CA, , USA, , Faith E. MetlockFaith E. Metlock , Johns Hopkins School of Nursing, , Baltimore, , MD, , USA, , Shirine MoukaledShirine Moukaled https://orcid.org/0000-0001-5421-8038 , Department of Epidemiology, , Tulane University School of Public Health and Tropical Medicine, , New Orleans, , LA, , USA, , Amy R. NicholsAmy R. Nichols https://orcid.org/0000-0002-3085-7377 , Department of Nutrition, , Harvard T.H. Chan School of Public Health, , Boston, , MA, , USA, , Department of Population Medicine, , Harvard Medical School, , Boston, , MA, , USA, , Harvard Pilgrim Health Care Institute, , Boston, , MA, , USA, , Bige OzkanBige Ozkan https://orcid.org/0000-0003-2745-1189 , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, , Johns Hopkins University School of Medicine, , Baltimore, , MD, , USA, , Rupal TrivediRupal Trivedi , Department of Clinical and Administrative Pharmacy, College of Pharmacy, , University of Georgia, , Athens, , GA, , USA, , Ruth‐Alma Turkson‐OcranRuth‐Alma Turkson‐Ocran https://orcid.org/0000-0001-9932-052X , Department of General Medicine, Beth Israel Deaconess Medical Center, , Harvard Medical School, , Boston, , MA, , USA, , Frances M. WangFrances M. Wang https://orcid.org/0000-0003-4950-582X , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Caroline WangCaroline Wang , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Welch Center for Prevention, Epidemiology, and Clinical Research, , Johns Hopkins University, , Baltimore, , MD, , USA, , Yunwen XuYunwen Xu https://orcid.org/0000-0002-5946-2272 , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Christina Y. YinChristina Y. Yin , Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, , Baltimore, , MD, , USA, , Mingyu ZhangMingyu Zhang https://orcid.org/0000-0003-3628-0983 , Department of Population Medicine, , Harvard Medical School, , Boston, , MA, , USA, , Harvard Pilgrim Health Care Institute, , Boston, , MA, , USA, , Alvaro AlonsoAlvaro Alonso https://orcid.org/0000-0002-2225-8323 , Department of Epidemiology, Rollins School of Public Health, , Emory University, , Atlanta, , GA, , USA, and Marie‐France HivertMarie‐France Hivert https://orcid.org/0000-0001-7752-2585 , Department of Population Medicine, , Harvard Medical School, , Boston, , MA, , USA, , Harvard Pilgrim Health Care Institute, , Boston, , MA, , USA, , Diabetes Unit, , Massachusetts General Hospital, , Boston, , MA, , USA, Originally published7 Oct 2023https://doi.org/10.1161/JAHA.123.029894Journal of the American Heart Association. 2023;12:e029894Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: October 7, 2023: Ahead of Print The 2023 American Heart Association (AHA) EPI|Lifestyle Scientific Sessions, cosponsored by the AHA Council on Epidemiology and Prevention (EPI) and the AHA Council on Lifestyle and Cardiometabolic Health (Lifestyle) to support research into population‐based approaches to reduce cardiovascular disease (CVD) and improve cardiovascular health (CVH), took place from March 1 to 3 in Boston, Massachusetts. The theme was “From Science to Action: Implementing Knowledge for Healthy Hearts” and featured implementation science approaches for applying CVD research in real‐world settings. A total of 876 participants, including trainees, public health professionals, and clinicians, attended the meeting, which featured 531 poster presentations, 78 moderated posters, and 69 oral presentations.1 The meeting was chaired by Dr Marie‐France Hivert, Harvard Medical School, representing the Lifestyle Council, and Dr Alvaro Alonso, Emory University, representing the EPI Council. The vice chairs were Dr Monica Serra, University of Texas (UT) Health San Antonio (Lifestyle), and Dr Priya Palta, University of North Carolina at Chapel Hill (EPI).Opening Remarks and Keynote SessionThe opening session began with an overview of this year's AHA initiatives from AHA president Dr Michelle A. Albert, University of California (UC), San Francisco. She emphasized the importance of translating scientific evidence into implementation, particularly among marginalized communities, and announced AHA's 2024 impact goal of advancing CVH for all by identifying and removing barriers to health care access.The first keynote speaker, Dr Crystal Wiley Cené, UC San Diego, highlighted existing evidence‐to‐practice gaps in implementation science research in achieving CVH equity. Evidence‐based interventions are often less effective in historically marginalized populations, and she called for equity‐minded, adaptive designs and more rigorous examination of implementation strategies.2Dr Josiemer Mattei, Harvard University, shared her work on developing an optimized Mediterranean diet specifically for Puerto Ricans and discussed culturally adapted diets for broader implementation in clinical and population‐based disease prevention programs.3 She also emphasized that translating evidence‐based programs takes time and researchers should trust their expertise and confidently implement their work.Dr Sara Bleich, Harvard University (formerly US Department of Agriculture), concluded the session with advice for turning research into policies and action. She stressed the importance of clear and effective communication when presenting evidence to policy stakeholders. A key takeaway: science can find solutions to pressing problems, but policy actions are needed to turn those solutions into reality.Memorial Lectures and Special SessionsDavid Kritchevsky Memorial LectureDr Shiriki Kumanyika, University of Pennsylvania, presented the David Kritchevsky Memorial Lecture, promoting implementation science as a pathway to equity‐competent obesity solutions. She shared context and considerations for conducting place‐based research including at faith‐based organizations, educational settings, and other community venues.An oral abstract session on nutrition followed Dr Kumanyika's lecture. First, Dr Valerie Sullivan, Johns Hopkins University, found that greater ultra‐processed food intake is associated with chronic kidney disease progression and increased risk of all‐cause death in adults with chronic kidney disease. Dr Katherine Mills, Tulane University, showed that a randomized trial of a dietitian‐led dietary sodium reduction intervention significantly reduced dietary sodium and blood pressure (BP) in patients with chronic kidney disease and albuminuria. Kenny Mendoza, PhD student from Harvard University, found that women with higher long‐term ultra‐processed food intake, particularly sugary drinks and animal‐based products, had a higher CVD risk, even with an otherwise high‐quality diet. Finally, Dr Howard Sesso, Brigham and Women's Hospital, reported findings from a pilot study showing that cocoa extract and multivitamin supplementation may alter the gut microbiome.Frederick H. Epstein Memorial Lecture and Cardiometabolic Risk PredictionThe Frederick H. Epstein Memorial Lecture, “Reimagining Prevention, Aspiring to Global Health Equity in a Post‐COVID‐19 World,” was given by Dr Sandro Galea, Boston University. His talk, which discussed the implications of COVID‐19 on future health promotion and disease prevention techniques, emphasized that reimagining public health should center around equity, use better science to guide decision making, and include self‐awareness by researchers for more consequential scholarship.An oral abstract session on cardiometabolic risk prediction followed Dr Galea's lecture. Dr Rosangela Hoshi, Brigham and Women's Hospital, showed that an immunoglobulin G N‐glycan–based score was positively associated with cardiovascular events, with reproducible results in 2 randomized trials. Dr Yoriko Heianza, Tulane University, found that comprehensive metabolomic risk scores were strongly related to the risk of incident coronary heart disease (CHD) events among women and that diet may mediate associations between CHD risk–related metabolites and atherosclerotic CVD risk. Dr Jose Medina‐Inojosa, Mayo Clinic, applied artificial intelligence algorithms to ECGs to detect coronary calcification. The coronary calcification–ECG algorithm was independently associated with long‐term atherosclerotic CVD events and improved risk models. Finally, Dr So Mi Jemma Cho, Broad Institute, showed that high genetic predisposition to CHD, low high‐density lipoprotein cholesterol, and younger age at primary CHD event most strongly explained CHD recurrence; however, the majority of CHD recurrence risk remained unexplained.William B. Kannel Memorial Lectureship in Preventive CardiologyDr Lori Mosca, Columbia University, presented the William B. Kannel Memorial Lecture. Her talk, “The Power of Patterns, Pioneers and Prevention,” discussed the evolution of CVD epidemiology from the Framingham Heart Study, which began >70 years ago, to the present. She noted that despite overall improvements, biological sex‐based disparities in CVD identification, presentation, and treatment are still present. She concluded with the need for equity and mentorship and emphasized the need to recognize the potential in the current generation of scientists and health care workers.An oral abstract session on preventive cardiology followed Dr Mosca's lecture. Dr Veronica McCloskey, Cano Health, presented results of a nurse practitioner–led program that led to improvements in reaching low‐density lipoprotein and systolic BP targets. Dr Angela Thompson‐Paul, Centers for Disease Control and Prevention, found that lipid screening in US youth was underused, but varied by age, body mass index (BMI), and race and ethnicity. Using data from the National Health and Nutrition Examination Survey, Dr Nour Makarem, Columbia University, found that the new Life's Essential 8 (LE8) score was a strong predictor of all‐cause, CVD, and cancer‐related death in US adults. In the final presentation, Dr Xuan Wang, Tulane University, found that in the UK Biobank Study, a high level of CVH, evaluated using metrics from LE8, was associated with longer life expectancy free of major chronic diseases.AHA Guidelines and StatementsDr Seth Martin, Johns Hopkins University, presented the 2023 AHA Heart Disease and Stroke Statistics.4 This report provides the latest data on heart and circulatory disease conditions and associated outcomes, emphasizing health equity and the impact of structural racism on health. Dr Michael Grandner, University of Arizona, introduced the LE8 checklist for assessing CVH.5 Updated from Life's Simple 7, LE8 introduces a sleep health metric and updates existing metrics such as diet, nicotine exposure, and blood glucose. Dr Nathalie Moise, Columbia University, presented the AHA Scientific Statement on leveraging implementation science for CVH equity.2 The statement offers a road map and checklist with health equity considerations for selecting, adapting, and evaluating evidence‐based practices and implementation strategies to reduce cardiovascular disparities. Dr Gbenga Ogedegbe, New York University, shared the latest developments related to the Health Equity Research Network on Prevention of Hypertension. This network, which received $20 million in funding from the AHA, brings together researchers from >8 institutions to address racial disparities in CVH outcomes by implementing evidence‐based hypertension prevention interventions in community settings. Dr Sadiya Khan, Northwestern University, emphasized the importance of prepregnancy CVH to reduce the risk of adverse pregnancy outcomes and cardiovascular disease for both birthing individuals and their offspring.6 She highlighted the need for a life‐course and intergenerational approach that addresses structural racism and inadequate health care through community‐level interventions and policy changes.Annual American Society of Preventive Cardiology DebateThe annual American Society of Preventive Cardiology debate focused on universal screening of lipoprotein(a) [Lp(a)], a variant of low‐density lipoprotein cholesterol. Dr Allan Sniderman, McGill University, argued for universal Lp(a) screening, and Dr Ann Marie Navar, UT Southwestern, argued that the evidence for universal screening is currently insufficient. The session was moderated by Dr Erin Michos, Johns Hopkins University.Dr Sniderman opened with evidence of the associations between Lp(a) and CVD, which are independent of traditional risk factors. He asserted that Lp(a) testing provides a more comprehensive assessment of patients' overall cholesterol levels than low‐density lipoprotein alone. Therefore, he argued, Lp(a) levels could be valuable for enhancing CVD risk stratification and guiding medicinal management, especially in young people.Dr Navar responded that there are few cases in which Lp(a) testing would change the clinical management of patients, particularly in low‐ and high‐risk populations. Dr Navar called for more studies to provide a better understanding of longitudinal changes in Lp(a), especially after lipid‐lowering therapy.The audience argued for potential benefits of incorporating Lp(a) in practice, including managing familial hypertension, primary CVD risk screening, and medication/therapeutic adherence. Drs Sniderman, Navar, and Michos finally agreed that Lp(a) is a promising biomarker in preventive cardiology, but further research is needed into its potential clinical implications on risk prediction and medical management.Cardiovascular Behavioral Medicine and Implementation ScienceThe session on cardiovascular behavioral medicine was planned in collaboration with the Society of Behavioral Medicine. Moderators Dr Allison Gaffey, Yale University, and Dr Laura Hayman, University of Massachusetts–Boston, began the session by describing cardiovascular behavioral medicine, a health psychology specialty. Dr Alyssa Vela, Northwestern University, and Dr Gaffey discussed the cardiovascular behavioral medicine philosophy and opportunities for stigma reduction and increased access to care in CVD management.Following these talks, oral abstracts highlighted the importance of integrating health behaviors into cardiovascular medicine. In a randomized crossover trial, Dr Keith Diaz, Columbia University, demonstrated that varying frequency and duration of breaks from sedentarism improved blood glucose, systolic BP, mood, and fatigue. Dr Christopher Kline, University of Pittsburgh, showed that better sleep was associated with increased adherence to lifestyle modifications, including session attendance, adherence to calorie goals, and increased physical activity (PA) in a behavioral weight loss intervention trial. Dr Li Yi, Harvard University, presented novel methods for evaluating behavioral, lifestyle, and environmental exposures in future cardiometabolic research using smartphone‐collected data, including location, accelerometer, sleep, and social network use. Finally, in a cluster‐randomized trial, Dr Joreintje Mackenbach, Amsterdam University Medical Centers, showed that supermarket nudging and pricing strategies did not improve individuals' purchasing and dietary behaviors.Oral AbstractsHealth Disparities and Social Determinants of HealthDr Utibe Essien, UC Los Angeles, began the session by showing that higher medication copays among patients with diabetes or heart failure were associated with lower medication adherence, even after adjusting for income and socioeconomic status. Adam Whalen, Albert Einstein College of Medicine, using the HCHS/SOL (Hispanic Community Health Study/Study of Latinos), showed that downward mobility (moving from higher socioeconomic status in childhood to lower socioeconomic status in adulthood) was associated with increased all‐cause death. Dr Timiya Nolan, The Ohio State University, described the development of a community initiative to uplift and empower Black women. Nicholas Roberts, MD student at Weill Cornell Medicine, found increased prevalence of hypertension and CVD among Haitians living in neighborhoods with high social vulnerability. Dr Ifedioranma Anikpo, University of Miami, showed that compared with US‐born Black adults, Black immigrants had a lower risk of obesity and hypertension. However, longer time spent in the United States attenuated this benefit, suggesting that US acculturation may play a role in the development of cardiometabolic disease. Dr Wayne Lawrence, National Cancer Institute, using the MESA (Multi‐ethnic Study of Atherosclerosis) found that experiences of lifetime and everyday discrimination were associated with increased CVD‐related death among Black individuals, particularly among Black men.Cardiometabolic Health and DiseaseStarting off the session, Dr Nwabunie Nwana, Houston Methodist, showed that exposure to higher levels of particulate matter ≤2.5 μm was associated with a greater prevalence of hypertension, diabetes, smoking, and obesity but not with dyslipidemia. Shirine Moukaled, PhD student from Tulane University, demonstrated that Black participants and those with lower socioeconomic status in the Bogalusa Heart Study had a greater multimorbidity burden—most commonly dyslipidemia, hypertension, and diabetes. Zailing Xing, PhD student from the University of South Florida, evaluated insulin resistance patterns in the ARIC (Atherosclerosis Risk in Communities) study, and showed that women with “high‐decreasing” insulin resistance trajectory had higher risk of death. Stably high insulin resistance was associated with increased risk of heart failure among both men and women. Dr Hokyou Lee, Yonsei University, derived a modified Life's Simple 7 score and showed that individuals with lower cumulative CVH scores had higher risk of incident CVD. Rounding out the session, Dr Zakaria Almuwaqat, Emory University, showed that higher BMI was associated with greater risk of myocardial infarction and cardiovascular death but not with risk of stroke.Maternal and Child Cardiometabolic Disease PreventionNatasha Morales‐Ghinaglia, PhD student from Pennsylvania State University, began the session showing that circadian misalignment of the sleep–wake cycle in adolescents was linked with impaired cardiac autonomic modulation and may contribute to CVD risk. Tiange Liu, PhD student from Johns Hopkins University, showed that higher gut microbiome diversity in infants was associated with lower BP later in childhood, though only among infants breastfed for at least 1 year. Dr Siwen Wang, Harvard University, found that maintaining a normal BMI, not smoking, regular exercise, healthy diet, avoiding harmful alcohol intake, and multivitamin supplementation were associated with lower risk of adverse pregnancy outcomes. Emily Ash, Medical University of South Carolina, reported that women with prepregnancy hypertension, hypertensive disorders of pregnancy, and diabetes in pregnancy faced an increased risk of CHD and maternal all‐cause death within 5 years of delivery; non‐Hispanic Black women had higher risks than non‐Hispanic White women. Katherine Campbell, PhD student at Emory University, found that women giving birth in metro Atlanta who lived in regions with greater daytime racial segregation and income disparities had higher odds of hypertensive disorders of pregnancy than those living in regions with less segregation and lower income disparities. Finally, Dr Sofie Taageby Nielsen, Copenhagen University, demonstrated that preeclampsia was associated with increased risk of maternal future CVD and higher lipid concentrations in umbilical cord blood of their offspring.Mixing up the 'OmicsThe 'omics session featured presentations on genomics, microbiome, metabolomics, and proteomics. Dr Abbas Dehghan, Imperial College London, found genetic loci associated with carotid artery intima‐media thickness. In a Mendelian randomization analysis of these loci, they found evidence of a bidirectional relationship between carotid artery intima‐media thickness and hypertension. Dr Hao Ma, Tulane University, showed that higher DNA methylation of the gene TXNIP was associated with lower fasting glucose in midlife among participants from the Bogalusa Heart Study, particularly in those with a larger increase in BMI from childhood to adolescence. Dr Nicole Armstrong, University of Alabama at Birmingham, found that African Americans with a lower systolic BP polygenic risk score had a greater decrease in systolic BP with chlorthalidone treatment and lower odds of developing treatment‐resistant hypertension. Dr Brandilyn Peters, Albert Einstein College of Medicine, showed an association between kidney function and gut microbiome diversity and composition in the HCHS/SOL. Dr Zhila Semnani‐Azad, Harvard University, found 23 metabolite networks and individual metabolites that were associated with child adiposity at age 5. Finally, Dr Bige Ozkan, Johns Hopkins University, found inflammatory and metabolic pathways that were associated with BMI, independent of traditional cardiovascular risk factors in the ARIC study.PA, Sedentary Behaviors, and SleepOpening the session on PA and sleep, Dr Aboubakari Nambiema, Université Paris Cité, showed that higher sleep scores and improving sleep scores over time were related to a lower risk of CHD. Dr Steve Nguyen, UC San Diego, found that higher sitting time and mean sitting bout duration were associated with higher CVD and all‐cause mortality risk among women. Dr Neela Thangada, Northwestern University, showed that in the CARDIA (Coronary Artery Risk Development in Young Adults) study, higher early adulthood cardiorespiratory fitness and its retention in midlife was associated with a lower risk of subclinical or clinical heart failure. Dr Mauro Mediano, Oswaldo Cruz Foundation, found that in HCHS/SOL, PA fragmentation, or having PA broken up into short bouts, was associated with death, independent of daily PA volume. Dr Minkyoung Song, Oregon Health and Science University, found that one‐third of US children did not meet the recommended sleep duration on the basis of LE8 criteria. Dr Erin Dooley, University of Alabama at Birmingham, showed that more daily steps were associated with lower risk of CVD events among older adults in the ARIC study.Jeremiah and Rose Stamler Research Award Finalist PresentationsThis year's Stamler award was presented to Dr Xiang Li from Tulane University. Dr Li observed that LE8, which adds a sleep health component, outperforms Life's Simple 7 at predicting CVH outcomes, including CHD, stroke, and CVD. Dr Hao Ma, Tulane University, found that at age 50, the average life expectancy was nearly 9 years longer among National Health and Nutrition Examination Survey participants with high CVH compared with participants with low CVH. Dr Bige Ozkan, Johns Hopkins University, found plasma proteins that were associated with both heart failure risk and obesity in middle‐aged adults from the ARIC study, which may indicate a mediating effect of these proteins in obesity‐related heart failure. Farah Allouch, PhD student from Tulane University, found that a 2‐question antihypertension medication adherence score was associated with BP control and CVD outcomes in multinational low‐income populations. Finally, Dr Nilay Shah, Northwestern University, reported that in middle‐aged adults from MESA, higher CVH was significantly associated with time lived free of coronary calcification, but no association was seen in older adults.Aging and Brain HealthKristine Moseholm, PhD student at the University of Copenhagen, showed that higher plasma levels of short‐chain ceramide and sphingomyelin were associated with faster cognitive decline, while higher levels of very‐long‐chain sphingomyelin were associated with lower risk of dementia and slower cognitive decline. Dr Nzechukwu Isiozor, University of Eastern Finland, found that a higher LE8 score was associated with a lower risk of stroke. Dr Jun Li, Brigham and Women's Hospital, found that the cortical transcriptomic profile for a Mediterranean‐style diet was associated with slower cognitive decline and lower odds of dementia. Dr Laura Skow, Johns Hopkins University, found that older adults who had diabetes and hypertension in midlife had faster physical function declines in late life. Using National Health and Nutrition Examination Survey data, Dr Aline Thomas, Columbia Unive

Molecular- and organelle-based predictive paradigm underlying recovery by left ventricular assist device support.

Withdrawal: Prospective Randomized Comparison Between Upgraded “2C3L” Versus PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT‐AF Trial Design

Sudden Cardiac Death Prediction And Prevention Report From A National Heart, Lung, And Blood Institute And Heart Rhythm Society Workshop

Right Ventricular Outflow Tract Electroanatomical Abnormalities Predict Ventricular Fibrillation Inducibility in Brugada Syndrome

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Is It Time to Reappraise Blood Pressure Thresholds and Targets?

Impact of Pulsatile Flow on Vital Organ Recovery During Cardiopulmonary Bypass in Neonates and Infants

Characteristics of Patients with Spontaneous Versus Drug-Induced Brugada Electrocardiogram: Sub-Analysis from the SABRUS

Central Blood Pressure Measurements and Antihypertensive Therapy: a Consensus Document.

Cardiovascular Disease Knowledge Portal: A Community Resource for Cardiovascular Disease Research

Highlights From the American Heart Association's EPI|Lifestyle Scientific Sessions 2023

Expert Consensus on Perioperative Medications During Endoscopic Submucosal Dissection for Gastric Lesions (2015, Suzhou, China)

Generation of a Self‐cleaved Inducible Cre Recombinase for Efficient Temporal Genetic Manipulation

Sex-specific Characteristics and Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.

Coronary Plaque Sampling Reveals Molecular Insights Into Coronary Artery Disease

Detection of Pathogens and Antimicrobial Resistance Genes Directly from Urine Samples in Patients Suspected of Urinary Tract Infection by Metagenomics Nanopore Sequencing: A Large-Scale Multi-Centre Study

Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)

The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect 18 F-Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series.

Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers

Association Between Cumulative Uric Acid Exposure and the Risk of Incident Cardiac Conduction Block

Long‐term Outcomes of Relapsed/refractory Double‐hit Lymphoma (r/r DHL) Treated with CD19/22 CAR T‐cell Cocktail Therapy